Your device is MDR-compliant. But is it approved for export?

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

This happens more often than it should. Manufacturers invest months preparing MDR-compliant clinical evaluations, only to discover that their target export markets demand additional clinical data, different standards, or specific post-market commitments that were never documented.

The assumption is simple: if it’s good enough for the EU, it’s good enough everywhere. That assumption costs time, money, and market access.

Why MDR Compliance Doesn’t Guarantee Export Readiness

The MDR establishes a comprehensive clinical evaluation framework. Article 61 requires manufacturers to demonstrate safety and performance through clinical data. The process is rigorous. Literature review. Equivalence demonstration or clinical investigations. PMCF to address residual uncertainties.

But the MDR is an EU regulation. It governs market access within the European Economic Area. It does not harmonize global requirements.

When you export a medical device, you enter jurisdictions with their own regulatory frameworks. Some align closely with the EU system. Others diverge significantly. The clinical evaluation that satisfies your Notified Body may not satisfy the regulatory authority in your target market.

The Core Disconnect: Different Evidence Standards

The problem starts with how different regulators define adequate clinical evidence.

Under MDR, you can demonstrate conformity through equivalence to a device already on the market, provided you meet the strict criteria in MDCG 2020-5. You compare your device to a similar device with established safety and performance. You justify clinical, technical, and biological equivalence. If the equivalence holds, you leverage existing clinical data.

Many regulatory authorities outside the EU do not accept equivalence claims. They require clinical data generated specifically for your device. Not similar devices. Your device.

Brazil’s ANVISA, for example, often requests clinical studies conducted within the Brazilian population when the device represents new technology or addresses a condition with population-specific characteristics. Australia’s TGA accepts equivalence in some cases but requires justification of why overseas clinical data applies to the Australian population.

If your CER relies entirely on equivalence to another manufacturer’s device, you may find yourself unable to enter these markets without generating new clinical data.

Standards Recognition

Another disconnect appears in harmonized standards.

The EU publishes a list of harmonized standards under the MDR. When you demonstrate compliance with these standards, you gain a presumption of conformity with the relevant essential requirements. This is foundational to the EU system.

Outside the EU, regulators may not recognize the same standards. They may require compliance with ISO standards the EU doesn’t list, or they may mandate local testing even when you’ve already demonstrated compliance with an equivalent international standard.

I’ve seen manufacturers assume that ISO 10993 biocompatibility testing conducted for MDR would automatically satisfy US FDA or Health Canada. It usually does, because those jurisdictions recognize ISO 10993. But when you move into markets like China or India, additional testing on different sample populations may be required.

Your clinical evaluation must account for this. You need to identify which standards apply in your target markets and ensure your clinical data addresses them.

Market-Specific Clinical Data Requirements

Let me walk through what different markets commonly require beyond MDR compliance.

United States (FDA)

The FDA operates under a different paradigm. Class I and many Class II devices may qualify for 510(k) clearance through substantial equivalence, similar conceptually to MDR equivalence. But the FDA’s definition of substantial equivalence differs. The predicate device must be legally marketed in the US. You must demonstrate technological and performance characteristics that are substantially equivalent.

For devices requiring Premarket Approval (PMA), the FDA expects clinical trial data from studies conducted under an approved Investigational Device Exemption (IDE). Literature reviews and equivalence claims rarely suffice. You need prospective data, often from US sites, with statistical power to support safety and effectiveness claims.

Your MDR-compliant CER won’t satisfy PMA requirements unless it includes this level of clinical investigation.

China (NMPA)

China’s NMPA has evolved significantly in recent years. Clinical evaluation requirements now resemble the EU system more closely, but differences remain.

For higher-risk devices, NMPA often requires clinical trials conducted in China, even when extensive international data exists. The rationale is to confirm safety and performance in the Chinese population. Ethnic differences in anatomy, disease prevalence, and treatment patterns justify this requirement from the regulator’s perspective.

NMPA also evaluates clinical trial design rigorously. Endpoints must align with Chinese clinical practice. Comparator devices must be marketed in China. Statistical analysis must follow specific methodologies.

If your CER relies on European clinical data without considering NMPA’s expectations, your export application will face delays or rejection.

Japan (PMDA)

Japan’s PMDA accepts international clinical data in many cases, especially for devices with established safety profiles. But they require bridging data to demonstrate that the device performs equivalently in the Japanese population.

This might involve additional clinical studies in Japan, or it might involve literature review and analysis showing that ethnic factors don’t significantly affect device performance. The key is explicit justification.

PMDA reviews are thorough. Reviewers question every assumption. If your clinical evaluation doesn’t proactively address population differences, you will receive questions. Answering those questions takes time and may require new data collection.

Brazil (ANVISA)

ANVISA categorizes devices using a risk-based system similar to the EU but with some classification differences. For higher-risk devices or those incorporating new technology, ANVISA frequently requires clinical investigation data.

The challenge is that ANVISA’s guidance on when clinical studies are required isn’t always predictable. Devices classified as Class IIb in the EU might face clinical investigation requirements in Brazil that weren’t anticipated.

Your clinical evaluation strategy for export to Brazil must include contingency planning for potential clinical study requirements, even when the device doesn’t require a clinical investigation under MDR.

PMCF and Post-Market Requirements Across Jurisdictions

Post-market clinical follow-up under MDR Article 61(11) and detailed in MDCG 2020-8 is mandatory for most devices. You develop a PMCF plan, collect real-world data, and feed findings back into your clinical evaluation.

But PMCF expectations vary internationally.

Some markets require post-market surveillance without specifying clinical follow-up. Others mandate post-approval studies with defined timelines and reporting requirements. Still others expect ongoing registry participation or outcomes reporting to national databases.

When you design your PMCF plan for MDR, consider how it will satisfy export market requirements. Can the same study protocols serve multiple jurisdictions? Can your data collection methods address both EU and non-EU expectations?

I’ve seen manufacturers develop separate PMCF plans for different markets because they didn’t consider global requirements during initial planning. This creates redundancy, increases costs, and complicates data integration.

A better approach is to map post-market requirements across all target markets during clinical evaluation planning, then design a PMCF strategy that satisfies the most stringent requirements while remaining feasible.

Reporting Timelines

Vigilance reporting timelines also differ. MDR requires reporting serious incidents and field safety corrective actions to Competent Authorities and Notified Bodies within specific timeframes. Most export markets have their own vigilance systems with different definitions, timelines, and reporting formats.

Your clinical evaluation must acknowledge this. The Post-Market Surveillance plan, which informs PMCF, should identify which markets you’re targeting and commit to complying with each market’s vigilance requirements.

This seems administrative, but it’s clinically relevant. Different reporting thresholds mean different signals get captured and analyzed. If you’re only tracking incidents that meet MDR definitions, you might miss events that would trigger reporting in another jurisdiction.

Building a Global Clinical Evaluation Strategy

So how do you prepare a clinical evaluation that supports both MDR compliance and export readiness?

Start with market mapping during the planning phase. Before you finalize your clinical evaluation plan, identify every market where you intend to commercialize the device within the next five years. Include markets you’re considering as possibilities.

For each market, research:

• Regulatory classification and pathway
• Clinical data requirements (studies, literature, equivalence acceptance)
• Standards and testing requirements
• Post-market commitments
• Population-specific considerations

This research informs your clinical evaluation plan. You identify the highest bar for clinical evidence across all target markets, then design your evaluation to meet that bar.

Designing for the Highest Standard

If one target market requires a clinical investigation and another accepts equivalence, plan for the clinical investigation. The data generated will satisfy both markets. The reverse isn’t true.

If one market requires population-specific data, incorporate that population into your study design or plan a separate bridging study early. Waiting until after MDR approval to address population-specific requirements delays market entry and increases cost.

This approach requires upfront investment. You’re generating more data than MDR alone requires. But it accelerates global commercialization and avoids the scenario where your MDR-compliant device sits idle while you conduct additional studies for export markets.

Documentation Strategy

Your CER should explicitly address multi-market requirements.

In the appraisal of clinical data, note which studies or datasets apply to which populations. If you’ve conducted studies in multiple regions, analyze whether results are consistent across populations or if differences appear.

In the analysis of clinical data, discuss how your findings apply to different demographic groups, disease prevalence patterns, and healthcare environments. This demonstrates you’ve considered global applicability.

In your conclusions and PMCF plan, commit to monitoring performance across all commercialized markets and updating the clinical evaluation based on global post-market data.

This level of detail helps both your Notified Body review and your export applications. Regulators see that you’ve thought through global clinical performance, not just EU compliance.

The Timing Challenge

One practical challenge is timing. You can’t delay MDR submission indefinitely while gathering data for every possible export market.

The solution is phased planning.

Prioritize markets based on commercial importance and time to market. For critical markets you plan to enter immediately after CE marking, ensure your initial clinical evaluation includes all necessary data.

For secondary markets you plan to enter later, identify gaps in your current clinical evaluation and schedule additional data collection through PMCF or supplementary studies. Document this plan in your PMCF strategy.

This keeps your MDR submission on track while building toward global market access systematically.

Managing Regulatory Dialogue

Early dialogue with regulatory authorities in target markets can clarify requirements before you finalize your clinical evaluation strategy.

Many regulatory bodies offer pre-submission meetings or written guidance requests. Use these mechanisms to confirm whether your planned clinical evaluation will satisfy their requirements.

I’ve worked with manufacturers who assumed they understood a market’s requirements based on published guidance, only to learn during pre-submission dialogue that the regulator expected additional data or different analysis. Early dialogue prevents these surprises.

When the Device Changes for Export

Sometimes device modifications are necessary for specific markets. Labeling in local languages. Different power supplies. Modified accessories.

Even minor changes trigger questions about clinical evaluation. Is the modified device still covered by your existing clinical data? Do the changes affect safety or performance in ways that require new clinical evidence?

Under MDR, these questions are addressed through the clinical evaluation’s analysis of device modifications and their impact on clinical safety and performance. The same logic applies for export variants.

Document each market-specific variant in your technical documentation. Analyze whether clinical data for the base device applies to the variant. If differences could affect clinical performance, address them through additional testing, literature review, or clinical investigation.

This analysis should appear in your CER’s clinical evaluation plan and appraisal sections, making it clear to any reviewer that you’ve evaluated clinical implications of all device variants.

What This Means Practically

Planning clinical evaluation for export requires thinking beyond your immediate regulatory submission. It means:

Researching export market requirements before you finalize your clinical evaluation plan, not after you receive CE marking.

Designing clinical studies that address the highest standard of evidence required across all target markets, even when MDR would accept less.

Documenting global applicability explicitly in your CER, with analysis of how clinical data applies across different populations and healthcare environments.

Building PMCF strategies that satisfy multiple jurisdictions simultaneously, reducing duplication and improving data integration.

Maintaining dialogue with regulatory authorities in key markets to validate your approach before committing to expensive clinical studies.

This requires coordination between clinical, regulatory, and commercial teams early in device development. Clinical evaluation can’t be planned in isolation from market access strategy.

The alternative is the scenario I described at the beginning: a fully compliant device that can’t be exported because the clinical evaluation doesn’t support registration in target markets. Months or years of delay. Additional studies. Missed revenue.

The manufacturers who succeed in global markets are those who think internationally from the beginning. They see clinical evaluation not as a checkbox for CE marking but as the foundation for demonstrating safety and performance to regulators worldwide.

Your device might be MDR-compliant. But export readiness requires asking what each target market needs to see in your clinical evaluation before they’ll approve your device. Answer that question early, and your clinical evaluation becomes a global asset, not a European document that needs continuous supplementation.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.